Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07388277 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Start date changed from estimate of Jul 9, 2026 to Mar 30, 2026 · Site details revisedv5 Show 2 more changesShow less
    • Start date changed from estimate of Jul 9, 2026 to Mar 30, 2026
    • Site details revised
  2. Re-verified, no change to tracked fieldsv4
  3. Recruitment opened Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Trial Details
NCT Number NCT07388277
Lead Sponsor Marcela V. Maus, M.D.,Ph.D.
Collaborators: Bristol-Myers Squibb
Conditions Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov